Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space.
[mstock id="3020"]
[mstock id="3021"]
Latest News
Sorry, we couldn't find any posts. Please try a different search.
Join our Newsletter
Get the latest Company updates delivered to straight to your inbox.